广东聚石化学股份有限公司 独立董事候选人声明与承诺 本人陈桂林，已充分了解并同意由提名人广东聚石化学股份有限公司董事会 提名为广东聚石化学股份有限公司第七届董事会独立董事候选人。本人公开声明， 本人具备独立董事任职资格，保证不存在任何影响本人担任广东聚石化学股份有 限公司独立董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有五年以上法律、经济会计、财务、管理等履行独立董 事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》和上海证券交易所自律监 管规则有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 （离）休后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定（如 适用）； （五）中共中央组织部《关于进一步规范党政领导干部在企业兼职（任职） 问题的意见 ...

证券代码：688669 证券简称：聚石化学 公告编号：2025-041 广东聚石化学股份有限公司 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 7 月 30 日 14 点 30 分 召开地点：广东省清远市高新技术产业开发区雄兴工业城 B6 广东聚石化学 股份有限公司二楼会议室 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第二次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 1 号 — 规范运作》 等有关规定执行。 （七） 涉及公开征集股东投票权 无 二、 会议审议事项 网络投票起止时 ...

证券代码：688669 证券简称：聚石化学 公告编号：2025-038 广东聚石化学股份有限公司 第六届董事会第二十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 广东聚石化学股份有限公司（以下简称"公司"）第六届董事会第二十九次 会议于 2025 年 7 月 14 日以现场结合通讯的方式召开，会议通知及相关材料于 2025 年 7 月 10 日以邮件、通讯形式送达公司全体董事。本次会议应出席董事 9 人，实际出席董事 9 人。会议由董事长陈钢先生主持，公司监事及高级管理人 员列席了本次会议。本次会议的召集、召开和表决程序符合《中华人民共和国 公司法》（以下简称"《公司法》"）、《上海证券交易所科创板股票上市规则》 等相关法律法规、行政法规、规范性文件和《广东聚石化学股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，会议决议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于取消监事会、修订<公司章程>及其附件并办理工商 变更登记的议案》 根据《公司法》的相关规定，结合 ...

Group 1 - The company aims to enhance operational capabilities by upgrading existing assets and processing isooctane and MTBE into finished gasoline to mitigate the negative impact of consumption tax [1] - The first phase of the project is expected to achieve 50% capacity utilization in its first full accounting year, generating revenue of 1.106 billion yuan and a net profit of 15 million yuan [1] - Upon full capacity, the project is projected to generate 2.213 billion yuan in revenue and a net profit of 35 million yuan [1] Group 2 - As of the end of 2024, the company's construction in progress amounts to 637 million yuan, an increase of 28.14% from the previous year [2] - The total budget for significant construction projects is 1.761 billion yuan, with a remaining balance of 558 million yuan [2] - Some projects have exceeded 100% completion but have not yet been transferred to fixed assets [2] Group 3 - The company has identified reasons for underutilization of capacity in major projects, including downstream demand, competition, and core product competitiveness [2][3] - Specific measures are being developed to improve capacity utilization, including price adjustments and enhancing product quality [2] - The company is actively exploring new markets, particularly in Africa, to boost sales [2] Group 4 - The company has a liquidity surplus after meeting operational and project funding needs, indicating no liquidity risk [9] - The company plans to optimize its organizational structure and focus on core business areas to improve its capital structure [9] Group 5 - The company acquired a 55% stake in Guan Zhen Technology for 60 million yuan, with performance commitments for net profits from 2022 to 2024 [10] - Guan Zhen Technology's actual net profits fell short of commitments, leading to a compensation obligation of 60 million yuan [10] - The company plans to transfer its stake in Guan Zhen Technology while ensuring compensation payments are made according to the agreed schedule [12] Group 6 - The company has reallocated goodwill among three asset groups, including Guan Zhen Technology, due to significant changes in the industry [15][19] - The reallocation of goodwill is in compliance with accounting standards and reflects the company's strategic adjustments [17][19]

Core Viewpoint - The company, Guangdong Jushi Chemical Co., Ltd., has received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, highlighting significant adjustments in its financial performance due to impairment losses and accounting errors related to its subsidiary, Guanzhen Technology [1][2]. Financial Performance Adjustments - The company corrected its 2024 annual performance forecast, revealing substantial discrepancies in operating profit, total profit, net profit attributable to shareholders, and earnings per share due to impairment losses totaling 43.62 million yuan [1][2][11]. - The adjustments included a 43.62 million yuan impairment loss for performance compensation related to Guanzhen Technology, 11.63 million yuan for fixed asset expense processing, 21 million yuan for intangible asset impairment, and 21.75 million yuan for fixed asset impairment in leasing business [1][2][11]. Business Background and Impairment Reasons - The company signed a share transfer agreement for Guanzhen Technology, with a total payment of 60 million yuan, and an additional 72 million yuan contingent on performance over three years [2][3]. - The performance commitments for Guanzhen Technology were adjusted, with net profit targets set at 12 million yuan, 18 million yuan, and 24 million yuan for 2022, 2023, and 2024 respectively [3][4]. - Due to continuous losses and unfavorable market conditions, the company reassessed the recoverability of performance compensation, leading to a significant reduction in the estimated value of Guanzhen Technology's shares [6][7]. Internal Control and Compliance Measures - The company acknowledged deficiencies in asset value confirmation and fixed asset depreciation management, prompting a comprehensive review and adjustment of its financial reporting processes [10][11]. - The management has implemented corrective measures, including enhancing internal controls and financial management practices, to prevent similar issues in the future [10][11]. Revenue and Profitability - For 2024, the company reported revenue of 4.08 billion yuan, a year-on-year increase of 10.72%, but a net loss of 236 million yuan, reversing from a profit of 29 million yuan in the previous year [11]. - The losses were attributed to impairment losses on assets related to Guanzhen Technology and increased costs associated with new business ventures still in development [11].

Core Viewpoint - The company, Guangdong Jushi Chemical Co., Ltd., has made significant adjustments to its financial forecasts and reports due to substantial impairment losses related to its subsidiary, Guanzhen Technology, and other asset evaluations, leading to a shift from profit to loss in its financial performance for 2024 [1][15]. Financial Performance - In 2024, the company reported operating revenue of 4.08 billion yuan, a year-on-year increase of 10.72% [15]. - The net profit attributable to shareholders was -236 million yuan, a reversal from a profit of 29 million yuan in the previous year [15]. - The non-recurring net profit was -206 million yuan, compared to -25 million yuan in the same period last year [15]. Adjustments and Impairments - The company corrected its earnings forecast due to significant adjustments in operating profit, total profit, net profit attributable to shareholders, and earnings per share, primarily due to impairment losses totaling 43.62 million yuan for performance compensation related to Guanzhen Technology [1][15]. - Specific impairment losses included 43.62 million yuan for performance compensation, 11.63 million yuan for fixed asset expenses, 21 million yuan for intangible assets, and 21.75 million yuan for fixed assets related to leasing [1]. Business Background and Agreements - The company acquired a 55% stake in Guanzhen Technology for 132 million yuan, with a payment structure based on the company's net profit over three years [4][5]. - Adjustments to the performance commitments for Guanzhen Technology were made, with minimum net profit targets set for 2022, 2023, and 2024 at 12 million yuan, 18 million yuan, and 24 million yuan, respectively [5]. Internal Control and Compliance - The company conducted a comprehensive self-examination and found no other accounting errors or necessary retrospective adjustments, indicating that internal controls related to financial reporting were not significantly deficient [12][13]. - The management has implemented corrective measures to enhance compliance and internal control, focusing on asset value accounting and fixed asset depreciation [12][13]. Customer and Supplier Information - The company provided detailed information on its top five customers and suppliers, including transaction amounts and changes in rankings, indicating a shift in customer dynamics and market conditions [16][18].

证券代码：688669 证券简称：聚石化学 公告编号：2025-037 广东聚石化学股份有限公司 关于上海证券交易所对公司 2024 年年度报告的 信息披露监管问询函的回复公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 广东聚石化学股份有限公司（以下简称"公司"）于近期收到上海证券交易 所出具的《关于广东聚石化学股份有限公司2024年年度报告的信息披露监管问询 函》（上证科创公函【2025】0157号）。公司高度重视有关问询事项，对相关事 项进行了核查，现将有关情况回复如下： 一、关于业绩预告及快报更正。4月29日，公司披露《2024年度业绩快报 暨业绩预告更正公告》，更正前后营业利润、利润总额、归母净利润、扣非 后归母净利润、每股收益差异较大。主要原因是：公司对冠臻科技的业绩补 偿款计提减值损失4,362万元、固定资产进行费用化处理1,163万元、无形资产 计提减值损失2,100万元、循环租赁业务固定资产计提减值损失2,175万元。 请公司：（1）逐项说明各个调整事项的计算方式、原因及合理性，相关 调整 ...

Core Viewpoint - The upcoming half-year report season is expected to show a positive trend in A-share companies' performance, with a significant number of companies forecasting profit increases, indicating a potential investment opportunity in high-growth sectors [1][2][4]. Group 1: Performance Forecasts - As of June 22, 2025, 18 A-share companies have disclosed their half-year performance forecasts, with 11 companies expecting profit increases, accounting for 61.11% of the total [1]. - Among the companies forecasting profit growth, notable increases include Shengnuo Biological (332.1%), Luxshare Precision (25%), and Jiao Da Iron & Steel (19.91%) [2]. - Six companies, including Luxshare Precision and Zhongce Rubber, are expected to achieve net profits exceeding 100 million yuan, with Luxshare Precision forecasting 6.745 billion yuan [2][3]. Group 2: Revenue Expectations - Eleven companies are projected to have revenues exceeding 500 million yuan, with five companies expected to surpass 1 billion yuan [3]. - Luxshare Precision leads in revenue expectations, while Zhongce Rubber anticipates revenue between 20 billion to 21.4 billion yuan, reflecting a year-on-year growth of 8% to 15.56% [3]. Group 3: Market Sentiment and Sector Insights - Analysts suggest that improving performance expectations can stabilize market sentiment and reduce short-term volatility, particularly in sectors like electronics and communications, which are benefiting from the AI industry's growth [4]. - The traditional Chinese medicine sector is also expected to see a performance turnaround, with analysts predicting significant revenue and profit growth in the second quarter of 2025 [4]. - Investment strategies should consider both short-term performance forecasts and long-term value growth commitments to support stable valuation increases [4].

Group 1 - The core viewpoint of the article highlights the strong performance of global IPO markets in the first half of 2025, with Hong Kong leading in IPO financing [1][7] - Deloitte's report indicates that Hong Kong's IPO financing reached 102.1 billion HKD, a significant increase of 673% compared to the previous year [7][9] - The A-share market also saw growth, with 50 new IPOs raising 37.1 billion RMB, reflecting a 14% increase in both the number of IPOs and financing compared to the previous year [3][6] Group 2 - Zhejiang province had two companies among the top five A-share IPOs, with Zhongce Rubber leading at 4.1 billion RMB [4][6] - The report anticipates that the A-share market will become more active in the second half of the year, particularly for high-tech companies, due to new policies from the China Securities Regulatory Commission [6][9] - Hong Kong's IPO market is expected to attract more companies, with over 170 listing applications in process, and a projected total financing of 200 billion HKD for the year [9]

Core Viewpoint - The company, Guangdong Jushi Chemical Co., Ltd., is undergoing a delay in some of its fundraising projects, which has been reviewed and approved by its board of directors, ensuring compliance with relevant regulations and maintaining the integrity of its investment plans [1][5]. Fundraising Overview - The company raised a total of RMB 855.1667 million through the issuance of 23.333334 million shares at a price of RMB 36.65 per share, with all funds received by January 19, 2021 [1][2]. - The raised funds are stored in a special account approved by the board, with a regulatory agreement in place with the sponsoring institution and the bank [2]. Investment Project Status - As of March 31, 2025, the total planned investment for the projects is RMB 1.2005951 billion, with cumulative investment amounting to RMB 552.4919 million, achieving a progress rate of 99.39% [3]. - The company has decided to conclude certain projects and reallocate surplus funds to enhance liquidity [3]. Delay Details - The delay in the "Chizhou Halogen-Free Flame Retardant Expansion Project" and "Anqing Polystyrene Production Project" is attributed to various factors, including climate conditions, construction capabilities, equipment debugging, and administrative approvals [4]. - The company has taken a cautious approach to control the investment pace of the "Anqing Polystyrene Production Project" due to external economic conditions and internal strategic adjustments [4]. Measures for Completion - The company plans to closely monitor market changes, expedite administrative approvals, optimize resource allocation, and enhance project supervision to ensure timely completion of the delayed projects [4]. Impact of Delay - The delay is a prudent decision based on actual project conditions and does not alter the investment content, total investment, or intended use of funds, thus not significantly impacting the company's normal operations or shareholder interests [4][5]. - The company will continue to adhere to regulatory requirements and strengthen both internal and external oversight of fund usage [5].